User profiles for A. Jon Stoessl

A Jon Stoessl OR jon Stoessl

University of British Columbia
Verified email at mail.ubc.ca
Cited by 31838

[HTML][HTML] Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

…, M Hulihan, RJ Uitti, DB Calne, AJ Stoessl… - Neuron, 2004 - cell.com
We have previously linked families with autosomal-dominant, late-onset parkinsonism to
chromosome 12p11.2-q13.1 (PARK8). By high-resolution recombination mapping and …

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open …

…, R Taylor, DA Cahn-Weiner, AJ Stoessl… - The Lancet …, 2008 - thelancet.com
Background There is an urgent need for therapies that slow or reverse the progression of
Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating …

Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

…, WJ Elias, ER Laws, V Dhawan, AJ Stoessl… - Annals of …, 2006 - Wiley Online Library
Objective Glial cell line–derived neurotrophic factor (GDNF) exerts potent trophic influence
on midbrain dopaminergic neurons. This randomized controlled clinical trial was designed to …

Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL‐PET study

AL Whone, RL Watts, AJ Stoessl, M Davis… - Annals of …, 2003 - Wiley Online Library
Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective
in Parkinson's disease (PD), and a pilot clinical study using 18 F‐dopa positron emission …

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

…, TJ Ruth, V Sossi, M Schulzer, DB Calne, AJ Stoessl - Science, 2001 - science.org
The power of placebos has long been recognized for improving numerous medical
conditions such as Parkinson's disease (PD). Little is known, however, about the mechanism …

Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

…, O Rascol, AD Korczyn, A Jon Stoessl… - Movement …, 2007 - Wiley Online Library
In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were
randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia …

Double-blind study of botulinum toxin in spasmodic torticollis

JKC Tsui, AJ Stoessl, A Eisen, S Calne, DB Calne - The Lancet, 1986 - Elsevier
including significant pain relief in 14 of the 16 patients forms of primary dystonia. There are
conflicting accounts of linkages Page 1 245 We thank Dr Elizabeth O’Byrne, Ciba-Geigy, New …

Alpha‐synuclein p. H50Q, a novel pathogenic mutation for Parkinson's disease

…, A Rajput, AH Rajput, A Jon Stoessl… - Movement …, 2013 - Wiley Online Library
Background Alpha‐synuclein plays a central role in the pathophysiology of Parkinson's
disease. Three missense mutations in SNCA, the gene encoding alpha‐synuclein, as well as …

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

…, DB Calne, AJ Stoessl - Annals of Neurology …, 2000 - Wiley Online Library
Clinical symptoms of Parkinson's disease (PD) do not manifest until dopamine (DA)
neuronal loss reaches a symptomatic threshold. To explore the mechanisms of functional …

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

…, Y Ding, R Brambilla, G Fisone, AJ Stoessl… - Progress in …, 2015 - Elsevier
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa)
therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …